Global pharmaceutical sales are expected to exceed $1.2 trillion in 2026, according to Statista. Worldwide oncology sales alone are projected to be $232 billion this year. Experts estimate an aging baby boomer generation will help fuel 4.7% annual pharmaceutical revenue growth, and global pharma sales will reach $1.5 trillion by 2030.
Pharmaceutical stocks can be excellent defensive investments during times of economic uncertainty, and many pharma stocks are also great sources of passive income thanks to their sizable dividend yields. Here are seven of the best pharmaceutical stocks to buy for income today, according to Argus Research analysts.
This post originally appeared at U.S. News & World Report.